key: cord-0776180-j62uv60r
authors: Gerhards, Catharina; Thiaucourt, Margot; Kittel, Maximilian; Becker, Celine; Ast, Volker; Hetjens, Michael; Neumaier, Michael; Haselmann, Verena
title: Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescent from COVID-19 infection
date: 2021-04-28
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.04.080
sha: 6fda972cc427f00c7e146a8a4308abe28ec4cdef
doc_id: 776180
cord_uid: j62uv60r

Introduction Longevity of anti-SARS-CoV-2 antibody level and duration of immunity are current topics of major scientific interest. Antibody kinetics during the acute phase are well-studied, whereas long-term kinetics are yet to be determined and available studies are controversial. Here, results of longitudinal analysis of serological responses to SARS-CoV-2 infection after convalescent and its association with post-COVID syndrome (PCS) are reported. Material and Methods 237 serum samples were prospectively collected from 61 SARS-CoV-2 qRT-PCR-confirmed participants. Anti-SARS-CoV-2 anti-N and anti-RBD/S1 Ig level were serially determined until 8 months after study inclusion. COVID-19 associated symptoms were assessed by a standardized questionnaire at study entry and after 6 months. Results Antibodies were detectable for 56/61 participants. Within the follow-up period, no substantial decline in the anti-SARS-CoV-2 pan-Ig levels were observed. In general, antibody levels were positively correlated with disease severity, BMI, fever, and nonsmoker status. 46.8% of the participants suffered from PCS, with olfactory and gustatory dysfunctions reported most frequently. Conclusion Study result point to stable anti-SARS-CoV-2 antibody titers and thus may indicate a long-lasting immunity. These results are in line with recently published data, and add further insights concerning asymptomatic to mild affected patients, the association with clinical features and the frequency of PCS.

The novel, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in December 2019 in Wuhan, China, as a pathogen causing critical respiratory infections termed coronavirus disease 2019 (COVID-19) (Zhou et al., 2020) . Within a few months, SARS-CoV-2 spread in China and finally resulted in a global pandemic (Ahn et al., 2020) . Until March 2021, over 118 million confirmed cases and more than 2.5 million fatalities have been reported worldwide as per WHO statistics (WHO, 2021) . Thus, there is a pressing need to understand the immune response induced by SARS-CoV-2 infection as well as the durability of immunity (Figueiredo-Campos et al., 2020) . This is of utmost importance for the future management of COVID-19 pandemic, especially in order to specify substainable vaccination strategies. For assessment of the efficacy and pattern of immune response to vaccination, the determination of seroprevalence and rate of reinfections, and the identifications of risk factors for post-COVID syndrome (PCS), a deeper understanding of the longevity of immunity and its association with disease severity or clinical presentation are mandatory (Sasisekharan et al., 2021) .

After infection with SARS-CoV-2, seroconversion usually occurs between 7-14 days after diagnosis (Krajewski et al., 2020 , Long et al., 2020a , Peeling et al., 2020 , with a peak in antibody levels observed around 30-35 days post-symptom onset (Crawford et al., 2020 , Isho et al., 2020 , Yao et al., 2020 . In contrast to this well-studied antibody kinetics during the acute phase, the longevity of antibody levels and durability of immunity following SARS-CoV-2 infection have not been fully elucidated due to the short time span since the onset of this novel disease. Moreover, the currently available studies are controversial. Some report a rapid decline of anti-SARS-CoV-2-specific IgG antibodies up to 3 month after infection (Beaudoin-Bussieres et al., 2020 , Ibarrondo et al., 2020 J o u r n a l P r e -p r o o f 2020), whereas others report stable titers over several month emphazising long-lasting immunity (Gudbjartsson et al., 2020 , Isho et al., 2020 , Yao et al., 2020 . Hence, further studies are warranted to verify results either in the one or other direction.

Here, we report the results of a prospective, longitudinal study of serologic response to SARS-CoV-2 and clinical presentation of 61 individuals. The disease severity ranged from asymptomatic courses to intensive care unit (ICU) patients, representing the full spectrum of SARS-CoV-2 infection. Serological response was assessed by measuring antibodies directed against the nucleocapsid (N) protein as well as the receptor-binding domain (RBD) of the spike (S) 1 sub-domain of SARS-CoV-2. For RBD/S1, protective immunity mediated by neutralizing antibodies was shown to correlate well with IgG antibodies targeting RBD/S1 of SARS-CoV-2 (Okba et al., 2020 , Robbiani et al., 2020 , Suthar et al., 2020 , and thus SARS-CoV-2-RBD/S1 antibody levels likely correlate with protective immunity. The main aims of this study were to (i) evaluate anti-SARS-CoV-2 antibody dynamics up to a period of 8 months, and (ii) to identifiy a possible correlation of antibody levels with disease severity, demographic factors, and the likelihood of developing PCS.

J o u r n a l P r e -p r o o f

From April to December 2020, participants were prospectively recruited at the University Medical Center Mannheim, Germany, as part of the Immunitor Study ((UMM), 2020).

Individuals age 18 and above with qRT-PCR confirmed SARS-CoV-2 infection after convalescence and PCR negativity, were eligible for inclusion. The study protocol was approved by the Institutional Review Board (2020-556N) and was conducted in accordance with the Declaration of Helsinki. Informed written consent was obtained from each subject prior to study inclusion, sample collection and analysis.

Sociodemographic and medical data were collected using a standardardized questionnaire on Research Electronic Data Capture (REDCap), a secure web platform for online databases and surveys supported by the University of Heidelberg (University) . Collected data included time of PCR positivity for SARS-CoV-2, clinical symptoms, type of treatment (e.g. outpatient, hospitalized, ICU), demographic data, and medical comorbidities. Study participants completed the questionnaire at time of enrollment and were asked for lasting COVID-19 symptoms after 6 months. All data were documented in pseudonymized form.

Sixty-one participants met the above mentioned inclusion criteria and provided serial blood samples for analysis of anti-SARS-CoV-2 antibody levels. Specifically, participants were asked to provide blood samples at 5 time points: time of study enrollment, after two weeks, after one month, after three months and after six months. At each time point, 7.5 ml serum were collected. Serum samples were stored at room temperature for at least one hour to ensure adequate clotting. Clotted samples were centrifuged at 2000 g for 10 minutes at 18°C. Serum was aliquoted and stored at -80°C until further use. A total of 237 serum samples were collected and used for anti-SARS-CoV-2 antibody detection. The following time intervals were J o u r n a l P r e -p r o o f combined for further statistical analysis: t0=0-50 days, t1=50-100 days, t2=100-150 days, t3=150-200 days and t4= 200-250 days.

Anti-SARS-CoV-2 anti-N and anti-RBD/S1 antibodies were determined in all samples. Analysis was performed as previously decribed (Haselmann et al., 2020) . Briefly, anti-SARS-CoV-2 anti-N total Ig was determined using the Elecsys® anti-SARS-CoV-2 assay (Roche, Germany), a qualitative electrochemiluminescence immunoassay (ECLIA) that is FDA approved and CE marked. Anti-SARS-CoV-2 anti-RBD/S1 total Ig was analyzed by using the Elecsys® Anti-SARS-CoV-2 S (Roche, Germany) quantitative FDA approved, CE marked ECLIA. Results are reported as a cutoff index (COI) for anti-N and in U/ml for anti-RBD/S1, with a respective value above 1.0 and 0.8 considered positive. The tests were performed according to the manufacturer's instructions and after internal verification according to ISO 15189 in an accredited laboratory.

Clinical data were systematically collected via the REDCap platform. To assess the impact of clinical parameters on the presence of antibodies to SARS-CoV-2, further statistical analyses were performed in SPSS version 26 (e.g. t-test for independent samples, Spearman's rank correlation coefficient). For all statistical analyses, p-values < 0.05 were considered statistically significant and displayed with *, p < 0.01 was represented with **. Graphs were plotted using GraphPad 7.0, SPSS or R (version 3.6).

A total of sixty-one participants convalescent from COVID-19 infection were prospectively enrolled. Overall, 237 serum samples were collected between 18 days and up to 8 months post-symptom onset, representing a mean of 3.9 samples analyzed per patient. As displayed in Table 1 , the mean age was 46.4 years (range 18-76 years), the mean body mass index (BMI) was 25.4, and 59% of the participants were female. 90.2% of the participants did not require hospitalization, and only 3.3% were admitted to ICU. In general, the majority of patients suffered from olfactory and gustatory dysfunctions (70.1% and 73.7%) at time of diagnosis, followed by mucle pain (52.5%) and fever (49.2%).

At study inclusion, anti-SARS-CoV-2 anti-N and anti-SARS-CoV-2 anti-RBD/S1 antibodies were detected in 55/61 and 56/61 of the participants, respectively. This corresponds to a sensitivity of 90.2 and 91.8%. Only one discrepant result was observed between anti-SARS-CoV-2 anti-N and anti-RBD/S1 analyses. Here, a weak positive result (COI = 3.12) was obtained for anti-RBD/S1 and a negative result (COI = 0.43) for anti-N. Remarkably, these findings were confirmed during the subsequent four assessments. In total, five participants had a negative test results in both pan-Ig antibody tests, corresponding to a negativity rate of 8.2%. Noteworthy, 4/5 with an early negative sample did not develop detectable antibodies over time. For one person results could not be confirmed over time because the participant discontinued study participation.

The correlation of clinical symptoms at the time of diagnosis, assessed by a standardized questionnaire, and the anti-SARS-CoV-2 antibody level was analyzed for anti-RBD/S1 J o u r n a l P r e -p r o o f exclusively, as only this test allows quantitative determination of anti-SARS-CoV-2 Ig. A significant positive correlation was observed between mean anti-RBD/S1 antibody level and the severity of COVID-19 disease (spearman's rho: 0.437; p<0.001), the participant age (spearman's rho: 0.300; p=0.019), and body mass index (BMI) (spearman's rho: 0.292; p=0.022). Higher BMI was also associated with a more severe disease (spearman's rho: 0.348; p=0.006). A comparison between smokers (n=4) and non smokers (n=57) showed significantly higher antibody levels in non-smoking participants (mean anti-RBD/S1 antibody level nonsmoking: 339.2 U/ml; mean anti-RBD/S1-level smoking: 88.4 U/ml; p=0.045). There was also a trend towards higher antibody levels in men compared to women (mean anti-RBD/S1level in male: 420.7 U/ml; mean anti-RBD/S1-level female: 254.6 U/ml; p=0.059). Detailed information on age, sex distribution, and anti-SARS-CoV-2 total IgG levels depending on the number of clinical symptoms is summarized in Table 1 .

Antibody kinetics over the observation period of 18 to 277 days after diagnosis are shown in Figure 1 . A total of 237 samples from sixty-one participants were serially analyzed for the presence and level of anti-SARS-CoV-2 anti-N and anti-RBD/S1 Ig, with an average of 3.9 sequential samples taken per individual. Over the complete observation period, 98.2% of initially seroconverted participants had detectable anti-SARS-CoV-2 anti-N antibodies and 100% had anti-SARS-CoV-2 anti-RBD/S1 antibodies at end of observation period 6-8 months after study inclusion. Noteworthy, no seroconversion was observed over time in participants with an intial COI < 1 (anti-N Ig) or < 0.8 U/ml (anti-S Ig), respectively.

When comparing t4 with t0/t1, anti-RBD/S1 Ig levels remained constant throughout (p=0.27), with a slight increase between t0/t1 and t2 (Figure 2 ; p=0.013 and p<0.01, respectively).

Nevertheless, an absolute decrease in the antibody level was observed for 13/56 when Comparable to the observed significant positive correlation between disease severity and anti-SARS-CoV-2 anti-RBD/S1 levels, antibody levels over time were higher on average in severely affected individuals (mean anti-RBD/S1-level in patients with > 5 clinical symptoms: 539.7+/-539.7 U/ml, compared to a mean result of 256.4+/-479.8 U/ml for participants with 1-5 and 64.2 +/-76.5 U/ml for asymptomatic individuals). Both disease severity and number of symptoms were significantly positively associated with the anti-N and anti-RBD/S1 IgG level.

However, no effect on antibody kinetics was observed. With respect to the various clinical symptoms commonly associated with COVID-19 infection, a significant positive correlation with anti-SARS-CoV-2 RBD/S1 level over time was revealed for fever (mean anti-RBD/S1-level without fever: 116.8 +/-221.1 U/ml ; mean anti-RBD/S1-level with fever 535.5 +/-609.2 U/ml; p<0.001). However, no significant association was observed for all other symptoms recorded with the questionnaire (Figure 3 ).

Six months after COVID-19 diagnosis, subjects were systematically asked about long-lasting COVID-19 symptoms. These long-term sequelae resulting from SARS-CoV-2 infection are J o u r n a l P r e -p r o o f commonly referred to as PCS. The response rate to the questionnaire was 77.1% (47/61 as 14 participants did not attend the last appointment). Of those who completed the questionnaire, 46.8% (22/47) reported persistent symptoms. The most frequently reported clinical symptom was olfactory or gustatory dysfunction (59%), followed by fatigue (36%), and other sporadically reported symptoms such as loss of hair, depressed mood, and lack of concentration. In general, women were more likely to have PCS compared to men.

Interestingly, 28% of the participants, who reported loss of smell and/or taste at study inclusion (77%), still suffered from impaired olfactory and gustatory function after six months follow-up. Another potential factor that could have an impact on the likelihood of developing a PCS is the disease severity during the acute phase. Accordingly, the symptom severity of the study participants was quantified and assessed in relation to the occurrence of a PCS.

However, no statistically significant difference in disease severity was revealed between patients with PCS and those without symptom persistence (p=0.554). Importantly, no siginificant correlation was observed between mean anti-RBD/S1 Ig levels over the observation period and the presence of long-term effects (anti-RBD/S1-level without longterm-effects 354.6+/-408.9 U/ml; mean anti-RBD/S1-level with long-term effects: 299.3+/-548.7 U/ml; p=0.7).

Anti-SARS-CoV-2 serologic testing is currently a topic of major scientific interest as it can be used to determine seroprevalence, contact tracing, definition of efficacy and pattern of immune response to vaccination, prediction of re-infection risk and duration of immunity following SARS-CoV-2 infection (Sasisekharan et al., 2021) . A detailed understanding will likely have major impact on sustainable vaccinations strategies. However, peer-reviewed publications addressing the longevity of anti-SARS-CoV-2 antibody levels and the durability of immunity are limited and results are controversial. Here, we provide a comprehensive profile of anti-SARS-CoV-2 Ig levels and clinical presentation in a cohort of 61 participants with qRT-PCR confirmed SARS-CoV-2 infection after convalescence. Immune response was assessed over a period of up to eight months, and questions about long-term health outcomes were addressed.

Across the study population, the majority of participants (90.2%) were identified as seropositive by using both pan-Ig antibody tests. However, a divergent result between anti-N and anti-RBD/S1 testing was observed and confirmed during the observation period. Such abberant results have been described previously, with anti-N positivity alongside anti-S negativity in most cases (Brochot et al., 2020) . Of the five participants who had a negative test results in both assays at the time of study inclusion, 100% received negative test results at subsequent appointments. Thus, either qRT-PCR results were false positive or these participants never developed detectable antibody levels reactive to N or RBD/S1 following SARS-CoV-2 infection. Two of five participants had a asymptomatic infection, for which the absence of seroconversion and thus undetectable antibody levels have been described previously (Milani et al., 2020) . The other three were paucisymptomatic outpatients. Here, a weaker immune reponse has been revealed (Long et al., 2020b) , and comparable results have J o u r n a l P r e -p r o o f been reported by Gudbjartsson et al. (Gudbjartsson et al., 2020) and could be explained by predominantly antigen-specific B-and T-lymphocyte-driven immunity without development of measurable antibody levels.

In our study, there was a significant positive correlation between disease severity and mean anti-RBD/S1 levels. These results are consistent with many other studies reporting higher antibody titers in severely COVID-19-infected individuals (Crawford et al., 2020 , Salazar et al., 2020 , Zhao et al., 2020 . The underlying mechanism has not yet been fully elucidated but could be explained by a more triggered immune response or antibody-dependent enhancement that favors viral entry and thus triggers a stronger inflammatory response (Cao, 2020) . In line with previous reports (Simonnet et al., 2020) , disease severity was associated with a higher BMI, and accordingly, our study showed a positive correlation between BMI and anti-RBD/S1 Ig levels. Recently, the expression of the SARS-CoV-2 target host receptor, human angiotensinconverting enzyme 2 (ACE2) receptor, on the surface of adipose tissue was identified as the likely responsible pathophysiological mechanism (Hussain et al., 2020) . In addition to BMI, age, sex, and smoking status were associated with SARS-CoV-2 Ig level. While older participants and men were found to have higher antibody levels, smokers had lower anti-SARS-CoV-2 Ig levels. These findings are consistent with recently published studies reporting a lower prevalence of smokers among hospitalized patients (Gudbjartsson et al., 2020) . One possible contributing factor represents the tobacco mosaic virus, a non-pathogen singlestranded RNA virus that infects tobacco leaves and has been identified in the respiratory tract of smokers. This viral infection could lead to an activation of the immune system and thus provide a barrier to entry of the SARS-CoV-2 virus (de Bernardis and Busà, 2020).

To date, few studies have longitudinally examined anti-SARS-CoV-2 antibody levels following convalescence from COVID-19 infection (Beaudoin-Bussieres et al., 2020, Crawford et al., J o u r n a l P r e -p r o o f al., 2020, Sasisekharan et al., 2021 , Wheatley et al., 2021 , Wu F., 2020 , Yamayoshi et al., 2021 , Yao et al., 2020 , with contrasting data reported regarding longevitiy of the induced antibody response. Waning levels of anti-SARS-CoV-2 anti-N, anti-S2, anti-S1, anti-RBD1, and neutralizing antibody within several weeks have been reported (Beaudoin-Bussieres et al., 2020 , Ibarrondo et al., 2020 , Roltgen et al., 2020 , Wheatley et al., 2021 , with a more rapid decay of anti-N IgG levels compared to anti-S (Wheatley et al., 2021) . These reports raised concerns that anti-SARS-CoV-2 humoral immunity might not be long-lasting.

However, recently published studies emphasize the sustainability of antibody titers of up to three (Wheatley et al., 2021) , four (Crawford et al., 2020 , Gudbjartsson et al., 2020 , Isho et al., 2020 , Sasisekharan et al., 2021 , six (Figueiredo-Campos et al., 2020 , L'Huillier et al., 2021 , Wu F., 2020 , or seven months (den Hartog et al., 2021) , with some reporting an initial decay decelerating after a few weeks (Figueiredo-Campos et al., 2020 , Lumley et al., 2021 , Wu F., 2020 . These findings need urgent confirmation. Our results are consistent with these reports and even go beyond them by showing stable anti-SARS-CoV-2 anti-N and anti-S levels of up to eight months. In general the controversial findings regarding longevity of anti-SARS-CoV-2 antibodies may be associated with the different types of serological assays used, with our data obtained by an FDA-approved, CE-marked verified test performed in an accredited setting.

Like Wheatley et al. (Wheatley et al., 2021) , we also observed a decay for anti-N pan-Ig with a 2-fold decrease achieved in 12 participants within the observation period of 277 days.

However, none of the participants converted seronegative except for one case. For these participants, anti-RBD/S1 results remained positive demonstrating different antibody patterns during follow-up. For anti-SARS-Cov-2 anti-RBD/S1, a slight increase was observed within the J o u r n a l P r e -p r o o f first 2-4 weeks. This initial increase is usually observed after viral infection and is mediated by short-lived antibody-producing plasmablast. It is followed by a rapid decline before reaching a stable plateau maintained by long-living, antibody-producing plasma cells. (Smith et al., 1996) . However, our results could not prove an early decline in antibody levels. This could be due to the fact that a pan-Ig antibody test was used, which does not allow to discriminate between IgM and IgG levels. Additionally, participants were enrolled after convalescence from COVID-19 infection and thus, in some cases, several weeks after infection. Therefore, changes in the earlier immune response could be missed.

Our study showed significant higher anti-N and anti-RBD/S1 levels with more severe infection, higher number of clinical symptoms, and fever. This positive correlation with disease serevity has been reported previously (den Hartog et al., 2021 , L'Huillier et al., 2021 , Yamayoshi et al., 2021 . However, we could not confirm the correlation between disease severity and decrease in antibody levels over time reported by Yamayoshi et al. (Yamayoshi et al., 2021) . Thus, our data indicate stable antibody levels and long-lasting immunity independent of disease severity.

In addition, the impact of antibody dynamics, antibody level, and clinical features on the likelihood of developing a PCS was examined. PCS is defined as "signs and symptoms that develop during or after an infection consistent with COVID-19, continue more than 12 weeks and are not explained by an alternative diagnosis" (2020). Post-COVID symptoms were assessed six months after study inclusions. A PCS was identified in 46.8% of participants, and the frequency was comparable to recently published data (Moreno-Perez et al., 2021 , Pereira et al., 2021 . However, as participants were specifically asked about persistent symptoms and the symptoms reported, e.g. olfactory and gustatory dysfunctions or fatigue, cannot be objectified, overestimation is likely. Because the impact of PCS on one's own health perception J o u r n a l P r e -p r o o f as well as on the public health situation is considered to be very high, risk factors need to be identified. Our study confirmed that antibody level does not influence the risk of developing a PCS as did neither of the initial symptoms assessed by the questionnaire (Pereira et al., 2015) . Thus, analogous to the global study cohort of Moreno-Perez et al., the severity of SARS-CoV-2 infection during the acute phase was not identified as an indicator of the occurrence of long-term sequelae. However, when focusing on a severe COVID-19 cohort, independent predictors such as intensive-care and invasive mechanical ventilation were found to be significantly associated with the occurrence of PCS (e.g. dyspnea, fatigue, weakness) (Moreno-Pérez et al., 2021 , Nalbandian et al., 2021 . However, we were unable to confirm these findings, most likely due to the fact that only two participants in our study cohort received intensive care, and thus case numbers in our study are too small to identify statistically relevant predictors.

Limitations of this study include recruitment of participants from a single study site and small cohort size. However, this study is one of, if not the, largest study to date in terms of the number of participants continuously followed-up for an observation period of more than six months and whose antibody titers were determined in an accredited, diagnostic setting.

Studies that reported data for numerous patients determined antibody levels in different individuals at different time-points after SAR-CoV-2 infection, but did not conduct longitudinal follow-up of patients. Another limitation of this study is that neither neutralizing antibodies as the best surrogate of immunity nor T-and B-lymphocyte responses were determined. Therefore, the persistence of anti-SARS-CoV-2 anti-RBD/S1 levels revealed in this study does not necessarily refer to immunity, but it has been shown previously that neutralizing antibody levels correlate well with anti-S1 levels (Figueiredo-Campos et al., 2020 , Wu F., 2020 .

In conclusion, our result further support sustained humoral immunity in patients convalescent from COVID-19 infection, regardless of disease severity, as stable anti-SARS-CoV-2 anti-N and anti-RBD/S1 pan-Ig levels were detected up to eight months post-symptom onset. Together with recent findings of long-term cellular immune response driven by memory T-cells, this provides hope for long-lasting immunity and the success of vaccination programs in our fight against COVID-19 pandemic. In addition, we demonstrated that a substantial number of participants suffered from PCS. These findings need to be confirmed in further studies, as does the stability of antibody levels over the long-term, particularly in vaccinated individuals.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Box-plots for Anti-SARS-CoV-2 anti-RBD/S1 (U/ml) (y-axis) ) summarized for the following time points (t0/t1: 0-50 days after diagnosis; t2= 50-100 days after diagnosis; t3=100-200 days after diagnosis, and t4=200-300 days after diagnosis of SARS-CoV-2 infection) (x-axis) are shown for the 61 participants providing serial blood specimens. Box-whisker anti-RBD/S1-level plots illustrate the interquartile range as the box, the minimum and maximum values as the end ot the whiskers. Each dot highlights the results obtained for a single participant.

J o u r n a l P r e -p r o o f

The box-plots illustrate the mean anti-SARS-CoV-2 anti-RBD/S1 Ig level (y-axis) assessed in U/ml over time for patients suffering from a particular clinical symptom compared with participants unaffected by the respective symptom (x-axis). Interquartile ranges are displayed as boxes, with the median highlighted by a line and the minimum and maximum values forming the end of the whiskers. Outlier are indicated by ⃝ and *. Furthermore, the significance of the association between the two groups is shown: fever (✱✱: p<0.001), nightsweat (p=0.185), diarrhea (p=0.267), cough (p=0.537), dyspnea (p=0.862), mucle pain (p=0.147), anosmia/ageusia (p=0.698). 

Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

Anti-spike, Antinucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals

COVID-19: immunopathology and its implications for therapy

COVID-19 rapid guideline: managing the long-term effects of COVID-19. National Institute for Health and Care Excellence: Clinical Guidelines. London

Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection

A putative role for the tobacco mosaic virus in smokers' resistance to COVID-19

Persistence of antibodies to SARS-CoV-2 in relation to symptoms in a nationwide prospective study

Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset

Humoral Immune Response to SARS-CoV-2 in Iceland

Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples

Obesity and mortality of COVID-19. Metaanalysis

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients

Update on serologic testing in COVID-19

Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study

Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients

Antibody responses to SARS-CoV-2 in patients with COVID-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers

Serological follow-up of SARS-CoV-2 asymptomatic subjects

Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study

Post-acute COVID-19 syndrome

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease

Serology testing in the COVID-19 pandemic response

Antibody response to SARS-CoV-2 infection is not associated with Post-COVID-19 Syndrome in healthcare workers

Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma

Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset

High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation

The phenotype and fate of the antibodyforming cells of the splenic foci

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Antibody titers against SARS-CoV-2 decline, but do not disappear for several months

Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

A pneumonia outbreak associated with a new coronavirus of probable bat origin

We thank Ameli Götz, Angelika Duda, Marina Talamini, Sihem Aida, Romy Eichner and LauraMirbach for organizing the study and aliquoting of samples. We thank Ingrid Brechtel and

The authors have declared no conflicts of interest.